Debuting on October 1st, to enhance CDMO and biosimilar businesses
토토사이트추천 Biologics (CEO John Rim) announced on May 22 that it will spin off its biosimilar operations to form a new entity, 토토사이트추천 Epis Holdings. The restructuring separates its contract development and manufacturing (CDMO) business from its biosimilar unit, currently operated by 토토사이트추천 Bioepis.
Effective October 1, 토토사이트추천 Biologics will focus exclusively on its CDMO operations, while 토토사이트추천 Epis Holdings will assume full ownership of 토토사이트추천 Bioepis and manage all biosimilar-related activities. The spin-off is designed to eliminate potential conflicts of interest between the two businesses and enable tailored investment strategies for each. The company emphasized that the move will strengthen both corporate governance and shareholder value.
Shareholder approval for the spin-off is scheduled for September 16. Following the split, 토토사이트추천 Biologics and 토토사이트추천 Epis Holdings will be listed separately on October 29. Kyung-Ah Kim, CEO of 토토사이트추천 Bioepis, will also serve as CEO of the newly formed 토토사이트추천 Epis Holdings.
As part of the spin-off structure, shareholders will be allocated shares in both companies according to their current holdings, at a ratio of 0.6503913 shares of 토토사이트추천 Biologics to 0.3496087 shares of 토토사이트추천 Epis Holdings. Trading of 토토사이트추천 Biologics stock will be suspended from September 29 to October 28.
Post spin-off, 토토사이트추천 Biologics will operate as a pure-play CDMO, advancing a three-pronged strategy: expanding manufacturing capacity, diversifying its product portfolio, and strengthening its global production network. The company also plans to invest in new areas such as antibody-drug conjugates (ADCs), adeno-associated viruses (AAVs), and pre-filled syringes (PFS).
토토사이트추천 Epis Holdings will focus on accelerating biosimilar development through 토토사이트추천 Bioepis, targeting a pipeline of over 20 biosimilar candidates. The company will also invest in next-generation modalities and platform technologies.
CEO John Rim commented, “This decision enables us to adapt swiftly to a rapidly evolving global market. By focusing and specializing, we aim to enhance our competitiveness and accelerate our growth into a top-tier global biopharmaceutical leader.”